Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05865301 · ClinicalTrials.gov registry record
Outcomes in Pediatric and Young Adult B-Cell Malignancies After Commercially Available Immunotherapy
A clinical trial of Lymphoid Leukemia, sponsored by Stanford University.
- Recruiting
- Registry status
- 500
- Enrollment target
- 20
- Study locations
NCT05865301: Recruiting study of Lymphoid Leukemia, sponsored by Stanford University.
NCT05865301 is a study of Lymphoid Leukemia that is actively recruiting participants, run by Stanford University. The registered enrollment target is 500 participants, above the 23-participant average among 3 other Lymphoid Leukemia trials with a reported enrollment target (2074% higher). The trial reports 20 study locations across 16 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05865301, a study of Lymphoid Leukemia, is actively recruiting participants, sponsored by Stanford University.
- RECRUITING
- Registry status
- 500 participants
- Enrollment target
- 20
- Study locations
Study Summary
To use a consistent and standardized platform to retrospectively and prospectively study children and young adults with B cell malignancies receiving Immunotherapy, blinatumomab and/or inotuzumab ozogamicin.
Primary Outcome
Participant will take part in a one-time questionnaire to address CAR specific questions. WECARE survey, consists of questions used to identify seven unmet material needs (education, employment, food security, housing, childcare, household heat, language)
Conditions Studied
Interventions
- OTHER Questionnaire for patients receiving therapy
Study Locations (20)
California
- City of Hope Comprehensive Cancer Center - Duarte
- Stanford University - Palo Alto
- UCSF (Benioff Children's) - San Francisco
Florida
- University of Florida Health Science Center - Gainesville - Gainesville
- Johns Hopkins All Children's Hospital - St. Petersburg
Texas
- UT Southwestern/Simmons Cancer Center-Dallas - Dallas
- Cook Children's Medical Center - Fort Worth
Arizona
- Banner University Medical Center - Tucson - Tucson
Delaware
- Nemours Children's Hospital - New Castle
Illinois
- Ann & Robert H. Lurie Children's Hospital of Chicago - Chicago
Maryland
- Johns Hopkins University/Sidney Kimmel Cancer Center - Baltimore
Massachusetts
- Dana-Farber Cancer Institute - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 500 participants |
| Start Date | 2023-06-29 |
| Est. Completion | 2038-12-31 |
What NCT05865301 shows while recruiting
NCT05865301 is an observational study that tracks outcomes without assigning an intervention. The registered 500 participants enrollment target is mid-sized for trials with a published cap, above the 23-participant average among 3 other Lymphoid Leukemia trials with a reported enrollment target (2074% higher).
The record links to 1 condition, with Lymphoid Leukemia appearing as the primary indexed condition, and to 1 intervention - of which Questionnaire for patients receiving therapy is the first listed.
NCT05865301 names 20 study sites across 16 states, led by California, Florida, Texas.
Frequently Asked Questions
What is clinical trial NCT05865301 about?
NCT05865301 is a clinical study titled "Outcomes in Pediatric and Young Adult B-Cell Malignancies After Commercially Available Immunotherapy". To use a consistent and standardized platform to retrospectively and prospectively study children and young adults with B cell malignancies receiving Immunotherapy, blinatumomab and/or inotuzumab ozogamicin.
What is the current status of trial NCT05865301?
This trial is currently recruiting. The enrollment target is 500 participants. The study started on 2023-06-29. Estimated completion is 2038-12-31.
What conditions does trial NCT05865301 study?
This clinical trial studies the following conditions: Lymphoid Leukemia.
What interventions are being tested in trial NCT05865301?
The interventions under investigation include: Questionnaire for patients receiving therapy (OTHER).
Who is sponsoring clinical trial NCT05865301?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05865301 being conducted?
This trial has 20 study locations across Arizona, California, Delaware, Florida, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lymphoid Leukemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Myeloablative Conditioning Orca-T & Allogeneic Donor-Derived CD19/CD22-CAR TCells in B-Cell ALL
ACTIVE NOT RECRUITING · Phase 1
-
Integrated Actionable Aging Assessment for Cancer Patients Pilot
ACTIVE NOT RECRUITING · NA
-
Vyxeos(CPX-351) in Adults w R/R Acute Lymphoblastic Leukemia
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00001230 · 500 participants
Host Response to Infection and Treatment in Filarial Diseases
- NCT00001529 · 500 participants
Improved Methods of Cell Selection for Bone Marrow Transplant Alternatives
- NCT00697411 · 500 participants
Study of Selected X-Linked Disorders: Aicardi Syndrome
- NCT00903110 · 500 participants
Global Patient Registry to Monitor Long-term Safety and Effectiveness of Increlex® in Children and Adolescents With Severe Primary Insulin-like Growth Factor-1 Deficiency (SPIGFD).
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI